Discontinued — last reported Q1 '25
West Pharmaceutical Services Contingent consideration fair value adjustment increased by 11.1% to $3.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 25.0%, from $2.40M to $3.00M.
A charge indicates that acquired businesses are performing better than expected, while a gain indicates underperformance relative to initial earn-out targets.
This represents the periodic revaluation of liabilities related to future payments owed to sellers of acquired businesse...
Common in M&A-heavy industries; peers report this as 'Change in Fair Value of Contingent Consideration'.
nee_contingent_consideration_fair_value_adjustment| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $200.00K | $100.00K | $800.00K | $300.00K | $1.50M | $300.00K | $500.00K | $700.00K | $1.00M | $1.00M | $1.20M | $2.40M | $2.20M | $2.70M | $3.00M |
| QoQ Change | — | -50.0% | +700.0% | -62.5% | +400.0% | -80.0% | +66.7% | +40.0% | +42.9% | +0.0% | +20.0% | +100.0% | -8.3% | +22.7% | +11.1% |
| YoY Change | — | — | — | +50.0% | >999% | -62.5% | +66.7% | -53.3% | +233.3% | +100.0% | +71.4% | +140.0% | +120.0% | +125.0% | +25.0% |